| scholarly article | Q13442814 |
| P2093 | author name string | Samir Malhotra | |
| A Bhalla | |||
| N Shafiq | |||
| J Ahluwalia | |||
| A Pareek | |||
| N Chandurkar | |||
| S Achuthan | |||
| P2860 | cites work | 11-Dehydrothromboxane B2: a quantitative index of thromboxane A2 formation in the human circulation | Q24630260 |
| Atherosclerosis — An Inflammatory Disease | Q26776972 | ||
| Effects of two preparations of 75-mg extended-release aspirin on platelet aggregation, prostanoids and nitric oxide production in humans | Q28192452 | ||
| A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease | Q28195458 | ||
| Effect of medication on microvascular vasodilatation in patients with systemic lupus erythematosus | Q33609077 | ||
| Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis | Q34648366 | ||
| Efficacy and safety of hydroxychloroquine in the treatment of type 2 diabetes mellitus: a double blind, randomized comparison with pioglitazone. | Q34660681 | ||
| Hydroxychloroquine improves insulin sensitivity in obese non-diabetic individuals | Q36246086 | ||
| 13-year long-term associations between changes in traditional cardiovascular risk factors and changes in fibrinogen levels: the Coronary Artery Risk Development in Young Adults (CARDIA) study | Q36487362 | ||
| Insights into atherosclerosis therapy in antiphospholipid syndrome | Q36984674 | ||
| Aspirin resistance: focus on clinical endpoints | Q37334879 | ||
| Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT). | Q37561659 | ||
| Use of hydroxychloroquine to prevent thrombosis in systemic lupus erythematosus and in antiphospholipid antibody-positive patients | Q37803363 | ||
| Acidic Ca(2+) stores in platelets | Q37822043 | ||
| Hydroxychloroquine and postoperative thromboembolism after total hip replacement | Q39531655 | ||
| Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature | Q40904739 | ||
| The antiphospholipid syndrome and SLE: is there a clue in the link between complement and coagulation? | Q40951725 | ||
| The unstable atheroma | Q41627468 | ||
| The effects of colchicine and hydroxychloroquine on the cyclo-oxygenases COX-1 and COX-2. | Q41914526 | ||
| Cardiometabolic and immune factors associated with increased common carotid artery intima-media thickness and cardiovascular disease in patients with systemic lupus erythematosus. | Q41921590 | ||
| Prevention of the platelet alpha-granule release reaction by membrane-active drugs | Q41923635 | ||
| Hydroxychloroquine use associated with improvement in lipid profiles in rheumatoid arthritis patients | Q41933145 | ||
| On the inhibitory effect of chloroquine on blood platelet aggregation | Q41935192 | ||
| Vascular elasticity of systemic lupus erythematosus patients is associated with steroids and hydroxychloroquine treatment | Q41942164 | ||
| Chloroquine treatment influences proinflammatory cytokine levels in systemic lupus erythematosus patients | Q41945144 | ||
| Prevalence and correlates of metabolic syndrome in patients with rheumatoid arthritis in Argentina. | Q44056335 | ||
| Effects of interleukin-1β inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial | Q45369180 | ||
| P433 | issue | 2 | |
| P921 | main subject | hydroxychloroquine | Q421094 |
| P304 | page(s) | 174-180 | |
| P577 | publication date | 2014-08-14 | |
| P1433 | published in | Journal of Cardiovascular Pharmacology and Therapeutics | Q1855644 |
| P1476 | title | Hydroxychloroquine's Efficacy as an Antiplatelet Agent Study in Healthy Volunteers: A Proof of Concept Study | |
| P478 | volume | 20 |
| Q59808719 | Antiphospholipid Syndrome and the Neurologist: From Pathogenesis to Therapy |
| Q38360827 | Chloroquine analogues in drug discovery: new directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases |
| Q55208303 | Chloroquine and hydroxychloroquine are associated with reduced cardiovascular risk: a systematic review and meta-analysis. |
| Q93250708 | Covid-19 treatment update: follow the scientific evidence |
| Q92118099 | Dermatologists' Adherence to the Latest Recommendations for Screening of Hydroxychloroquine Retinopathy in Saudi Arabia: Cross-Sectional Study |
| Q36877859 | Hydroxychloroquine Use Is Associated With Decreased Incident Cardiovascular Events in Rheumatoid Arthritis Patients |
| Q53609113 | Hydroxychloroquine for the prevention of recurrent cardiovascular events in myocardial infarction patients: rationale and design of the OXI trial. |
| Q39440991 | New Insights on Platelets and Platelet-Derived Microparticles in Systemic Lupus Erythematosus. |
| Q48274065 | Primary prevention of cardiovascular disease in patients with systemic lupus erythematosus: case series and literature review. |
| Q49787347 | The association between hydroxychloroquine treatment and cardiovascular morbidity among rheumatoid arthritis patients |
| Q38561490 | Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases |
Search more.